Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response
- PMID: 37735622
- PMCID: PMC10512508
- DOI: 10.1186/s12014-023-09429-6
Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response
Abstract
Background: Type 1 diabetes (T1D) results from an autoimmune attack of the pancreatic β cells that progresses to dysglycemia and symptomatic hyperglycemia. Current biomarkers to track this evolution are limited, with development of islet autoantibodies marking the onset of autoimmunity and metabolic tests used to detect dysglycemia. Therefore, additional biomarkers are needed to better track disease initiation and progression. Multiple clinical studies have used proteomics to identify biomarker candidates. However, most of the studies were limited to the initial candidate identification, which needs to be further validated and have assays developed for clinical use. Here we curate these studies to help prioritize biomarker candidates for validation studies and to obtain a broader view of processes regulated during disease development.
Methods: This systematic review was registered with Open Science Framework ( https://doi.org/10.17605/OSF.IO/N8TSA ). Using PRISMA guidelines, we conducted a systematic search of proteomics studies of T1D in the PubMed to identify putative protein biomarkers of the disease. Studies that performed mass spectrometry-based untargeted/targeted proteomic analysis of human serum/plasma of control, pre-seroconversion, post-seroconversion, and/or T1D-diagnosed subjects were included. For unbiased screening, 3 reviewers screened all the articles independently using the pre-determined criteria.
Results: A total of 13 studies met our inclusion criteria, resulting in the identification of 266 unique proteins, with 31 (11.6%) being identified across 3 or more studies. The circulating protein biomarkers were found to be enriched in complement, lipid metabolism, and immune response pathways, all of which are found to be dysregulated in different phases of T1D development. We found 2 subsets: 17 proteins (C3, C1R, C8G, C4B, IBP2, IBP3, ITIH1, ITIH2, BTD, APOE, TETN, C1S, C6A3, SAA4, ALS, SEPP1 and PI16) and 3 proteins (C3, CLUS and C4A) have consistent regulation in at least 2 independent studies at post-seroconversion and post-diagnosis compared to controls, respectively, making them strong candidates for clinical assay development.
Conclusions: Biomarkers analyzed in this systematic review highlight alterations in specific biological processes in T1D, including complement, lipid metabolism, and immune response pathways, and may have potential for further use in the clinic as prognostic or diagnostic assays.
Keywords: Biomarker; Plasma; Proteomics; Type 1 diabetes.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10512508/bin/12014_2023_9429_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10512508/bin/12014_2023_9429_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10512508/bin/12014_2023_9429_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10512508/bin/12014_2023_9429_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10512508/bin/12014_2023_9429_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10512508/bin/12014_2023_9429_Fig6_HTML.gif)
Update of
-
Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response.medRxiv [Preprint]. 2023 Feb 22:2023.02.21.23286132. doi: 10.1101/2023.02.21.23286132. medRxiv. 2023. Update in: Clin Proteomics. 2023 Sep 21;20(1):38. doi: 10.1186/s12014-023-09429-6. PMID: 36865103 Free PMC article. Updated. Preprint.
Similar articles
-
Mass Spectrometry-Based Proteomics for Discovering Salivary Biomarkers in Periodontitis: A Systematic Review.Int J Mol Sci. 2023 Sep 27;24(19):14599. doi: 10.3390/ijms241914599. Int J Mol Sci. 2023. PMID: 37834046 Free PMC article. Review.
-
Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response.medRxiv [Preprint]. 2023 Feb 22:2023.02.21.23286132. doi: 10.1101/2023.02.21.23286132. medRxiv. 2023. Update in: Clin Proteomics. 2023 Sep 21;20(1):38. doi: 10.1186/s12014-023-09429-6. PMID: 36865103 Free PMC article. Updated. Preprint.
-
Circulating biomarkers during progression to type 1 diabetes: A systematic review.Front Endocrinol (Lausanne). 2023 Feb 3;14:1117076. doi: 10.3389/fendo.2023.1117076. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36817583 Free PMC article.
-
Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.Cochrane Database Syst Rev. 2023 Feb 22;2(2):CD013775. doi: 10.1002/14651858.CD013775.pub2. Cochrane Database Syst Rev. 2023. PMID: 36815723 Free PMC article. Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
Cited by
-
Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes.BMJ Open Diabetes Res Care. 2024 Feb 27;12(1):e003924. doi: 10.1136/bmjdrc-2023-003924. BMJ Open Diabetes Res Care. 2024. PMID: 38413173 Free PMC article.
-
Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes.iScience. 2023 Dec 20;27(2):108769. doi: 10.1016/j.isci.2023.108769. eCollection 2024 Feb 16. iScience. 2023. PMID: 38303689 Free PMC article.
-
A proteomic meta-analysis refinement of plasma extracellular vesicles.Sci Data. 2023 Nov 28;10(1):837. doi: 10.1038/s41597-023-02748-1. Sci Data. 2023. PMID: 38017024 Free PMC article.
-
Fatty acid-mediated signaling as a target for developing type 1 diabetes therapies.Expert Opin Ther Targets. 2023 Jul-Dec;27(9):793-806. doi: 10.1080/14728222.2023.2259099. Epub 2023 Sep 14. Expert Opin Ther Targets. 2023. PMID: 37706269 Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous